Grace HalimChief Data Officer

Grace Halim · Chief Data Officer · Singapore / Southeast Asia

My responsibility grew from preparing observations to explaining the institution’s data account.

Mar 2020 — Present

Chief Data Officer

Seravune Therapeutics

Sector
Therapeutics research and development
Ownership
Private group; founder interests 38%, long-term institutional investors 62%
Company scale
S$1.86 billion company revenue in 2025
Employees
3900 company employees at October 2026
Geography
Singapore headquarters; research collaboration across Southeast Asia and international partners
Reporting to
Chief Executive Officer
Team
105 data colleagues through six direct reports
Financial scope
S$16.8 million delegated 2026 function expense; scientific portfolio and technology capital separately authorised

Mandate

Make source, measurement and transformation context available to the experts judging research evidence.

Outcomes

  • Preserved 6800 missing baseline values in an 18000-record registry rather than coding them as normal findings.
  • Retained method families across 240000 readings from twelve studies pending scientific and statistical comparability review.
  • Reported forty-nine replayed analyses and fifteen missing dependency versions within a sixty-four-analysis archive exercise.

Decisions in context

The CDO appointment connected research-data practice with the institution's wider account of its evidence. I began executive board presentations in March 2020 and had to explain why a complete table or successful software replay could still leave a scientific question unresolved. The registry, cross-study and archive cases each required a boundary between what the data programme established and what the responsible experts needed to judge. I wanted the board to understand that boundary without treating every qualification as a failure of the programme. My function expense supports the data practice; it does not give me authority over clinical safety, product decisions or the research portfolio. The role has made me interested in how a board asks for evidence about its evidence processes. That interest remains a proposed next contribution, with no statutory director service claimed in the fictional record.

Reason for the move

Current executive role; a prospective first statutory seat would need separate preparation, permission and assessment.

Sept 2013 — Feb 2020

Vice-President, Enterprise Data

Seravune Therapeutics

Sector
Enterprise data for a therapeutics research group
Ownership
Privately held founder-led group with long-term institutional investment
Company scale
S$980 million company revenue in 2019
Employees
2600 company employees in 2019
Geography
Singapore-based research functions and collaborating international teams
Reporting to
Chief Operating Officer
Team
68 data colleagues through five direct reports
Financial scope
S$9.2 million annual enterprise-data expense at 2019

Mandate

Improve the discovery and explanation of research datasets without overstating their suitability or resulting benefit.

Outcomes

  • Curated metadata for thirty-seven research datasets through the 2017 programme.
  • Recorded median retrieval changing from eleven to four business days across twenty-six matched request pairs in a six-month comparison.
  • Kept the S$1.6 million programme result bounded to retrieval and shared team contribution, without a clinical-benefit claim.

Decisions in context

Enterprise data required me to judge which improvements should proceed while a larger technology decision remained open. The metadata programme was useful because locating a dataset and understanding its purpose were problems a replacement platform would not automatically solve. Research and technology colleagues contributed alongside my team, and the measured retrieval result belonged to that combined effort. I wanted the account to retain the twenty-six matched request pairs rather than turn a sample result into a claim about every research activity. The role broadened my responsibility beyond individual studies while keeping scientific use decisions with the relevant owners. Becoming CDO followed the need for a more coherent institutional explanation of those relationships. It added board-facing responsibility and a wider remit, without converting better access into evidence that a dataset was appropriate for any proposed scientific conclusion.

Reason for the move

Appointed CDO to extend the data account across source context, research interpretation and institutional oversight.

Jul 2005 — Aug 2013

Head of Research Data

Seravune Therapeutics

Sector
Research-data management within therapeutics development
Ownership
Private founder-led research company
Company scale
S$420 million company revenue in 2012
Employees
1400 company employees in 2012
Geography
Singapore research operations and regional study collaboration
Reporting to
Research Operations Director
Team
31 research-data colleagues through four direct reports
Financial scope
S$3.9 million annual research-data expense at 2012

Mandate

Preserve the relationship between recorded observations and their research source context.

Outcomes

  • Withdrew the 2011 description of 2700 replicate readings as 2700 independent samples.
  • Retained 900 source samples and three readings per sample in the corrected record.
  • Supported S$480000 review while leaving statistical inference with the responsible specialists.

Decisions in context

Joining the therapeutics company made the history of a research record a continuing institutional responsibility. I would still be present when material was revisited for a later question, which made the source relationship especially important. The replicate-reading mistake occurred during that period. I had to separate the useful laboratory observations from the incorrect independent-sample claim I had added to their count. The correction strengthened my attention to labels and row meaning, but it did not make me the authority for every statistical inference. The team worked with researchers and specialists to preserve an account they could assess. Progression to enterprise data came as these needs extended across the organisation. I wanted a reader finding an unfamiliar dataset to understand its origin and limitations without relying entirely on the memory of the team that first assembled it.

Reason for the move

Promoted to enterprise data to connect study-level data practice with the group’s wider information needs.

May 1996 — Jun 2005

Research Project Lead

Nalverin Research

Sector
Research data and analytical project services
Ownership
Fictional privately held research-services firm
Company scale
S$34 million company revenue in 2004
Employees
190 company employees in 2004
Geography
Singapore and Southeast Asian research assignments
Reporting to
Managing Director
Team
19 project colleagues through three direct reports
Financial scope
S$1.1 million annual project-function expense at 2004

Mandate

Coordinate the data record so scientific and statistical owners can assess its intended use.

Outcomes

  • Made source conditions and observation scope part of research-data delivery accounts.
  • Distinguished completion of a data assignment from suitability for every later analytical question.
  • Built the coordination experience needed for an internal research-data leadership appointment.

Decisions in context

Project leadership brought responsibility for the quality of an account prepared by several colleagues. I needed to understand what the scientists and statisticians required while keeping their professional judgements separate from my delivery role. A dataset could meet the assignment's agreed preparation requirements and still be unsuitable for a different question. I wanted that distinction to survive the handover. The company's revenue and employment described the services business; my expense authority concerned a nineteen-person project group. I did not acquire a client's scientific decision rights through that delegation. The move into Seravune followed an interest in what happened after delivery, when records were reused, interpretations changed and the original team might no longer be available. An internal appointment offered the opportunity to develop that continuity rather than treating each handover as the end of the data story.

Reason for the move

Joined Seravune Therapeutics to develop a continuing data practice within a research institution.

Jul 1988 — Apr 1996

Research Analyst

Nalverin Research

Sector
Research analysis and data preparation
Ownership
Private research-services company
Company scale
S$7.6 million company revenue in 1995
Employees
60 company employees in 1995
Geography
Singapore; regional research-support assignments
Reporting to
Project Manager
Team
Analyst in an eight-person group; no line-management authority
Financial scope
No expenditure delegation or scientific-decision authority

Mandate

Explain the source and meaning of observations used in an analytical account.

Outcomes

  • Prepared research material with its recording purpose and observation scope retained.
  • Investigated unclear source relationships before interpreting a dataset total.
  • Developed the communication and coordination skills needed for project leadership.

Decisions in context

The first appointment followed my statistics degree and taught me to look behind the convenience of a table. I worked within an eight-person group, with experienced colleagues helping me understand the research context. My task was to prepare and examine observations, not to make scientific or spending decisions. I became interested in what a later reader would need to know if the source team was absent. A label, a recording condition or a relationship between repeated measurements could change the interpretation substantially. I did not understand every implication at the time, but I learned to keep questions visible rather than fill uncertainty with a plausible assumption. Project leadership followed as I became better able to explain the work and coordinate its delivery. It added responsibility for colleagues while preserving the boundary between the data account and the expert judgement it supported.

Reason for the move

Promoted after developing analytical review skills and the ability to coordinate a clear account for research users.

What I am looking for next

I would like to help a board understand the conditions behind its research-data evidence. A combined chart, a complete-looking registry or a replayed analysis can be useful while leaving important questions open. My cases offer ways to ask who should judge those questions and what the programme has actually established. I would include the replicate-reading error because a credible contribution should expose my own interpretive mistake as well as the decisions I defended.

I have no statutory directorship in this invented career. Twenty-four annual days could be discussed only with employer permission and a realistic account of induction, preparation, committee work and travel. Scientific collaborators, suppliers, investors and employment relationships would require review. A real appointment would need current professional guidance for its jurisdiction and conditions; this record claims no Indian independent-director databank registration or exemption. I would undertake further governance learning before moving from executive presentations to collective responsibility. The proposed next chapter is an evidence-management contribution to oversight, not a claim of clinical authority or an offer to assess a visitor's research findings.